热门资讯> 正文
Emergent BioSolutions获得6000万美元合同
2026-03-26 04:21
- Emergent BioSolutions (EBS) announced on Wednesday it has secured a contract award valued at approximately $54M to deliver CNJ-016® to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness.
- In addition, Emergent has secured new incremental orders with an international government partner valued at $6.6M. This represents product orders for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) within Emergent’s medical countermeasures portfolio and will support the partner’s smallpox biodefense strategy.
- The announcement follows Emergent’s recent execution of multi-year agreements with the Government of Canada valued at up to C$140M to support the country’s biologic threat preparedness and response infrastructure, of which more than C$35M in orders will be received in 2026.
- Source: Press Release
More on Emergent Biosolutions
- Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture
- Emergent BioSolutions plummets on weak 2026 revenue guidance, Q4 results
- Emergent BioSolutions outlines $720M–$760M 2026 revenue target as transformation plan advances
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
